Distinct initiating events underpin the immune and metabolic heterogeneity of KRAS-mutant lung adenocarcinoma

The KRAS oncoprotein, a critical driver in 33% of lung adenocarcinoma (LUAD), has remained an elusive clinical target due to its perceived undruggable nature. The identification of dependencies borne through common co-occurring mutations are sought to more effectively target KRAS-mutant lung cancer....

Descripción completa

Detalles Bibliográficos
Autores principales: Best, Sarah A., Ding, Sheryl, Kersbergen, Ariena, Dong, Xueyi, Song, Ji-Ying, Xie, Yi, Reljic, Boris, Li, Kaiming, Vince, James E., Rathi, Vivek, Wright, Gavin M., Ritchie, Matthew E., Sutherland, Kate D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6744438/
https://www.ncbi.nlm.nih.gov/pubmed/31519898
http://dx.doi.org/10.1038/s41467-019-12164-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6744438/
https://www.ncbi.nlm.nih.gov/pubmed/31519898
http://dx.doi.org/10.1038/s41467-019-12164-y

Ejemplares similares